Physician profile
Mark John Piotrowski
NPI 1417059114
$7,819.36
in general payments reported to CMS, 2019-2025
26 companies · $1,327 in 2025
The $1,327 reported for 2025 was more than what 83% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,120 · 2020: $219 · 2021: $790 · 2022: $1,401 · 2023: $1,041 · 2024: $922 · 2025: $1,327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,289.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $1,734.18 | 2019-2025 | Tecnis Simplicity, Tecnis Iol |
| Abbvie INC. | $1,292.76 | 2022-2025 | |
| Alcon Vision LLC | $1,236.92 | 2020-2025 | Clareon Panoptix Pro, Clareon, Acrysof Iq Panoptix Uv Iol |
| Bausch & Lomb Americas INC. | $623.09 | 2022-2025 | Xiidra, Miebo, Lotemax Sm |
| Allergan, INC. | $429.32 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $405.56 | 2019-2023 | |
| Rxsight INC | $376.13 | 2021-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Aerie Pharmaceuticals, INC. | $248.88 | 2019 | |
| Oyster Point Pharma, INC. | $228.82 | 2023-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Ocular Therapeutix, INC. | $178.21 | 2019-2024 | Dextenza |
| Harrow Eye, LLC | $161.18 | 2023-2025 | Vevye |
| Eyevance Pharmaceuticals LLC | $127.89 | 2021-2022 | |
| Dompe US, INC. | $119.90 | 2019 | |
| New World Medical,INC. | $115.69 | 2022-2023 | |
| Sun Pharmaceutical Industries INC. | $90.00 | 2022-2025 | Cequa |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $82.99 | 2024-2025 | Istent Infinite, Idosetr, Idose |
| Horizon Therapeutics Plc | $68.42 | 2019-2022 | |
| Sight Sciences, INC. | $64.22 | 2021-2023 | Omni Surgical System |
| Tarsus Pharmaceuticals, INC. | $45.07 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $43.94 | 2019-2021 | |
| Thea Pharma INC. | $43.81 | 2023-2024 | Iyuzeh |
| Kala Pharmaceuticals, INC. | $24.82 | 2021 | |
| Amgen INC. | $23.44 | 2025 | Tepezza |
| Mallinckrodt Hospital Products INC. | $19.68 | 2022 | |
| Ivantis, INC | $19.61 | 2020 | |
| Apellis Pharmaceuticals, INC. | $14.83 | 2025 | Syfovre |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Piotrowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.